Enhertu has been a major commercial success for AstraZeneca and Daiichi Sankyo, generating $3bn in revenue in 2023, as per the company financials. According to GlobalData’s Pharma Intelligence ...

India's pharmaceutical market is witnessing a surge in new drug launches, particularly in the oncology segment, fueled by a ...

Shares of solid tumor concern Zymeworks Inc. have barely budged since the company obtained its first approval. Click here to ...

“Without a commercial arrangement that results in a price that represents a cost-effective use of NHS resources, NICE cannot recommend Enhertu." Nearly 700,000 women will be recruited into an ...

For Enhertu, we anticipate new international launches ... in the broader ATTR cardiomyopathy indication. And following the commercial launch of Airsupra early last year, we have seen impressive ...

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...

AstraZeneca turned down an offer of nearly £80mn in UK state support when it abruptly cancelled plans for a £450mn vaccine manufacturing site near Liverpool, according to people briefed on the matter.

Keeping a lid on drug prices is proving costly for ambitions to turn the UK into a life sciences superpower ...

Alliance revenues included $392 million from Daiichi Sankyo for Enhertu and $133 million of ... Based on the commercial potential of these news drugs, AstraZeneca believes it can post industry ...